Christina DiArcangelo

🚀 Registration Now Open for the Oligonucleotide Therapeutics Xchange - Maryland 2024! 🚀 We are thrilled to share that registration is now open for hubXchange's Oligonucleotide Therapeutics Xchange Maryland 2024! This event will convene leading executives from the pharma and biotech sectors to tackle and find solutions for the critical challenges in Oligonucleotide Therapeutics. 📅 Date: Wednesday, October 30, 2024 🕗 Time: 8:00 AM - 6:15 PM 📍 Location: Maryland Join us to stay at the forefront of Oligonucleotide Therapeutics innovation and connect with fellow industry leaders. Don’t miss out—register today and get your Complimentary Pass! https://lnkd.in/eyChA_wt 🔎 Why Attend hubXchange? Take advantage of a unique platform that promotes knowledge exchange and industry connections. 🗣🔬 Featuring Industry Experts: Weiguo Zhai, Senior Director, R&D Analytical Sciences, BioPharmaceutical Development, AstraZeneca Xiaoyong Lu, M.S. Ph.D., Director of Oligonucleotide and Genetic Medicine, Eli Lilly and Company Antonio DiGiandomenico, Senior Director, AstraZeneca Jimmy Weterings, VP, Research RNA Therapeutics & Delivery, Sirnaomics Jeremy Little, Director of Custom Oligonucleotides, ChemGenes Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group Jeremy Little, Director of Custom Oligonucleotides, ChemGenes David Brown, Director, RNAimmune David Blackmon, Director, Alcyone Therapeutics Inc. Our Partners: 🤝 ChemGenes 🤝 PolyPeptide Group 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #OligonucleotideTherapeutics #Pharma #Biotech #hubXchange #Networking #Innovation #MarylandEvent #DrugDevelopment #RNAtherapeutics #GeneticMedicine #Biopharma #Pharmaceuticals #Biotechnology #LifeSciences #MedicalResearch #HealthcareInnovation #BiotechCommunity #ScientificConference #Therapeutics #BiotechInnovation #PharmaConference #ClinicalResearch #DrugDelivery #NewModalities #OligonucleotideDiscovery #PharmaNetworking #PharmaEvents #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

5

☕ #Boston, grab you favorite Dunkin’ coffee and join us at the Precision in Clinical Trials Summit May 6 & 7! Stop by Booth #11 to meet the #IDDI experts Tara Kervin & Kalyn D. to discuss how IDDI’s solutions can assist your most pressing clinical trial challenges. 📈 Schedule a meeting today: https://lnkd.in/efjcJffp #PCTSummit #biometricscro #clinicaltrials #biostatistics #datamanagement #lifesciences #trialdesign

10

In 2023 alone, practices in The Network participated in over 200 trials, enrolling more than 1,000 patients in treatment studies across various disease states. Read more in our 2023 Annual Report 📊 https://lnkd.in/g2khrtTR #ClinicalResearch #ClinicalTrials #CommunityOncology

33

Proud to be an Expertise Partner for the 12th Annual #Alzheimer's and #Parkinson's Drug Development Summit in Boston, MA, April 23-25. Alamar's Christopher Bunker, Ph.D., M.B.A. will be providing an exclusive look at #NULISA and its applications in CNS disease research. He'll also dive into the new #NULISAseq CNS Disease Panel 120 for ultra-sensitive and multiplex protein biomarker detection that includes #pTau217 and ~120 other important neurogenerative targets. https://ow.ly/Vqqm50Rlui4 #proteomics

41

COTA Announces Extended Collaboration with FDA to Advance the Use of Real-World-Data in Cancer Research New York, May 22, 2024–  Today, COTA announced an extension of its research collaboration with ​​the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence. Under the collaboration, the two organizations will continue to jointly develop and implement research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. This collaboration serves as an extension of the agreement between COTA and the FDA established in 2018. To date, the partnership has yielded numerous oncology research studies that have been presented at the annual meetings of the American Society of Hematology (ASH) and the American Association for Cancer Research (AACR). The collaboration has been extended for an additional 5 years, focusing on leveraging real-world evidence to strengthen regulatory decision-making. COTA and the FDA will evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer. “We are excited to continue our work with the FDA to explore the use of real-world data in oncology research and drug development,” said C. K. Wang, COTA’s chief medical officer. “Collaboration with institutions like the FDA are critical to advancing the speed and accuracy in which new drugs are evaluated and made available to patients.” This collaboration will facilitate the use of new oncology data sources to support the mission of the OCE Scientific Collaborative. Additionally, the collaboration will support a better understanding of the use of therapies and associated diagnostics in real-world settings, along with exploration of the modifiable and non-modifiable factors influencing outcomes in real-world practice to inform regulatory science objectives. #realworlddata #realworldevidence #fda #oncologyresearch #cancerresearch #pharma #oncology

111

3 Comments

In the fifth video of the series, "The Participant's Perspective on Clinical Research," Mike and Suzanne O'Brien share how the clinical research experience compared to their expectations before starting. Mike and Suzanne participated in clinical research for Alzheimer's disease at JEM Research Institute, a Headlands Research clinical trial site. #HeadlandsResearch #ClinicalTrials #ALZresearch #ClinicalTrialSites

1

Clinical team members Andrew Holt, PharmD, BCMAS, CPGx, and Savannah Roberts Clary, Pharm.D., BCPS, CPGx, were recently featured in Drug Topics magazine as contributors to a two-part series on tianeptine. If you are not familiar with tianeptine, you should know that it is easily accessible in most states under brand names like Tianaa, Neptune’s Fix, and more. Use of tianeptine alone or in combination with other substances or prescription drugs can complicate patient management and increase their risk of drug interactions and harm. Tianeptine’s activity at opioid receptors helped it gain its nickname of “gas station heroin.” Testing for tianeptine in the healthcare setting can help with educating patients, as they may not voluntarily report use, and it can also help inform treatment decisions. Read more here: https://lnkd.in/e9uEAAkS #AegisLabs #Tianeptine #PublicSafety #Opioids #Overdose #OnePillCanKill #DrugInteractions

18

Association of Northern California Oncologists (ANCO)’s ASCO24 highlights panel discussion with Eric Small American Society of Clinical Oncology (ASCO) #ANCO #ASCO #ASCO24 #Cancer #OncoDaily #Oncology

19

Read about last week's webinar, "Seeing the Future of Gene Therapy," which focused on current options for clinical patients as well as new therapies. Michelle Alabek #webinar #lunchandlearn #ophthalmology #genetherapy #artificialvision #clinicaltrials #clinicaltrialprocess #CRISPR #futuredirections #geneticcounselors #inheritedretinaldystrophies #optogenetics #patienteligibility #PRFP31RP #retinitispigmentosa https://lnkd.in/eB-WJfay

2

A recent opinion piece in The Hill by Paul Alexander discusses the complex relationship between high drug prices and PBM rebates, shedding light on how these rebates can distort the market and negatively impact patients. While PBMs claim to negotiate lower drug prices, Pitts notes that the rebate system they manipulate often leads to higher list prices and increased out-of-pocket costs for patients. "Rebates create a perverse incentive for manufacturers to set higher list prices, knowing they must offer substantial rebates to secure formulary placement," Alexander explains. This issue is particularly relevant for independent #communityoncology practices, as the distorted market can affect drug availability and affordability for patients with cancer. The article calls for greater transparency and reform in the #PBM rebate system to ensure that savings are passed on to patients rather than benefiting intermediaries. Read the full article: https://lnkd.in/ene8XUaa

6

SPRING HOUSE, Pa., Nov. 7, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis (RA) who have tested positive for anti-citrullinated protein antibodies (ACPAs)a and/or rheumatoid factor (RF), and who have had an inadequate response or intolerance to at least one anti-tumor necrosis factor (anti-TNF) therapy. The data from this study establish proof of mechanism for nipocalimab in RA and support its progression into a combination study.1 IRIS-RA is the first clinical study to assess the efficacy and safety of the anti-neonatal Fc (FcRn)-driven MOA for the treatment of RA.2 The study findings, along with an acceptable benefit-risk profile, support the further investigation of nipocalimab in this refractory population.1 A trial investigating the efficacy and safety of nipocalimab in combination with an anti-TNFα treatment in patients living with RA has recently been initiated.3 Treatment with nipocalimab, an anti-FcRn receptor therapy, resulted in numerically greater improvements at Week 12 across primary and secondary efficacy endpoints including Disease Activity Score 28 using C-reactive protein (DAS28-CRP),b American College of Rheumatology (ACR) responses,c DAS28-CRP remission and Health Assessment Questionnaire – Disability Index (HAQ-DI).1,d A numerically greater number of patients in the nipocalimab group achieved ACR50 (n=5/33 nipocalimab versus n=1/20 placebo) and DAS28-CRP remission (n=7/33 nipocalimab versus n=2/20 placebo) compared with the placebo group.1 By selectively blocking the FcRn receptor, nipocalimab reduced levels of circulating immunoglobin G (IgG) antibodies, including ACPAs, indicating they may play a key role in driving RA disease activity.4 The placebo adjusted DAS28-CRP remission rate of a subpopulation of study participants with higher mean baseline levelse of ACPAs was more than double the overall study population (23.3 percent difference from placebo [n=27]; versus 11.2 percent difference from placebo [n=53] respectively).1,4 These data will be presented for the first time as an oral presentation at ACR Convergence 2023, taking place in San Diego, California on November 12, 2023.1 In addition, a poster (#2144) on the pharmacodynamic effects of nipocalimab in the IRIS-RA study will be presented at ACR.1,4 “There is an urgent need for new therapeutic avenues capable of reducing the impact of rheumatoid arthritis for more patients,” said Dr. Peter C. Taylor, MA, Ph.D., FRCP, FRCPE, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.f “Even with the use of the current targeted therapies, up to half of those living with rheumatoid arthritis do not reach remission or still have low disease activity. We

1

📢 Check out our report on the explosive growth of the Cell and Gene Therapy (CGT) industry in Greater Philadelphia! 🌟 #LeadingLifeSciences! The region is now the nation’s #2 CGT hub, serving as home to 60 of the estimated 500 CGT companies worldwide. Dive into the report here: https://lnkd.in/edNneij9

8

#MovingMedicineForward: Congratulations to our friends at ProKidney Corp. on their positive interim REGEN-007 Phase 2 data. The trial evaluating ProKidney’s renal autologous cell therapy, rilparencel, in #ChronicKidneyDisease (CKD) patients has demonstrated stabilized #Kidney functions over 18 months, with no rilparencel-related adverse events reported in any study patients. We highlight ProKidney for their commitment to advancing potential #Dialysis prevention & #HealthcareSolutions for individuals with #CKD. Learn more about their research in the article linked below!

26

In this Drug Target Review article, our CEO, John J. Puisis, discusses our versatile #nanoparticle platform and its potential to treat #AutoimmuneDiseases like #MyastheniaGravis and #Type1Diabetes. Read more here: https://bit.ly/3ySKjok

51

1 Comment